Biodesix, Inc. announced the appointment of internationally recognized lung cancer expert, James Jett, MD, as Chief Medical Officer. Dr. Jett joins Steven Springmeyer, MD as co-CMO to support all aspects of the Company’s research, development and commercialization efforts. Today’s news comes as Biodesix continues to drive adoption of the recently launched Nodify XL2 proteomic nodule classifier.
“Biodesix is a natural continuation of my gratifying career as a physician. I believe that the future of patient care in oncology and pulmonology should be designed and innovated with the patient experience as the highest priority”
Dr. Jett joins Biodesix from Oncimmune Ltd., where he served as the Chief Medical Officer. His career includes work as a Professor of Medicine at the Mayo Medical School and the University of Pittsburgh. Dr. Jett has also served as a consultant for the National Cancer Institute in Bethesda, and he was the Editor in Chief of the Journal of Thoracic Oncology from 2006-2013. His work on academic editorial boards includes Chest, Respiratory Medicine, and the American Journal of Respiratory and Critical Care Medicine.
